Nuveen’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-94,178
| Closed | -$150K | – | 3476 |
|
|
2024
Q1 | $150K | Sell |
94,178
-530,354
| -85% | -$787K | ﹤0.01% | 3220 |
|
|
2023
Q4 | $536K | Buy |
624,532
+742
| +0.1% | +$652 | ﹤0.01% | 2975 |
|
|
2023
Q3 | $667K | Sell |
623,790
-157,547
| -20% | -$326K | ﹤0.01% | 2738 |
|
|
2023
Q2 | $2.02M | Buy |
781,337
+12,453
| +2% | +$44.4K | ﹤0.01% | 2344 |
|
|
2023
Q1 | $3.14M | Buy |
768,884
+11,131
| +1% | +$51.4K | ﹤0.01% | 2143 |
|
|
2022
Q4 | $3.8M | Buy |
757,753
+18,943
| +3% | +$119K | ﹤0.01% | 2072 |
|
|
2022
Q3 | $9.66M | Buy |
738,810
+203,372
| +38% | +$3.08M | ﹤0.01% | 1490 |
|
|
2022
Q2 | $6.86M | Buy |
535,438
+288,412
| +117% | +$3.99M | ﹤0.01% | 1745 |
|
|
2022
Q1 | $3.75M | Sell |
247,026
-8,734
| -3% | -$136K | ﹤0.01% | 2211 |
|
|
2021
Q4 | $4.53M | Buy |
255,760
+79,824
| +45% | +$1.53M | ﹤0.01% | 2176 |
|
|
2021
Q3 | $4.05M | Buy |
175,936
+51,773
| +42% | +$1.14M | ﹤0.01% | 2327 |
|
|
2021
Q2 | $2.45M | Sell |
124,163
-48,513
| -28% | -$1.14M | ﹤0.01% | 2606 |
|
|
2021
Q1 | $5.02M | Buy |
172,676
+72,696
| +73% | +$2.04M | ﹤0.01% | 2172 |
|
|
2020
Q4 | $3.03M | Buy |
99,980
+6,143
| +7% | +$134K | ﹤0.01% | 2304 |
|
|
2020
Q3 | $1.49M | Sell |
93,837
-18,281
| -16% | -$333K | ﹤0.01% | 2498 |
|
|
2020
Q2 | $2.21M | Sell |
112,118
-2,320
| -2% | -$44.3K | ﹤0.01% | 2303 |
|
|
2020
Q1 | $1.41M | Sell |
114,438
-108,031
| -49% | -$1.76M | ﹤0.01% | 2359 |
|
|
2019
Q4 | $4.11M | Buy |
222,469
+198,635
| +833% | +$2.9M | ﹤0.01% | 2089 |
|
|
2019
Q3 | $330K | Buy |
23,834
+13,818
| +138% | +$207K | ﹤0.01% | 3036 |
|
|
2019
Q2 | $147K | Buy |
+10,016
| New | +$147K | ﹤0.01% | 3200 |
|
Nuveen's NGM Position: Q2 2024 in Review
Nuveen sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 94,178 shares — an estimated $150K sold.
Nuveen first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $9.66M in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Nuveen reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Nuveen sold 94,178 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $150K.
- Nuveen first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Nuveen's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $9.66M in Q3 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.